CapsoVision Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$15.6Mnext fiscal year
FY EPS (est.)
-$0.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cumulative Patient Procedures Quarterly167KTarget: Continued expansion of clinical use and procedure volume
Quarterly Revenue Quarterly2.8MTarget: Revenue growth in Q2 2026 and the second half of the year
Quarterly Capsule Shipments Quarterly6.2KTarget: Expansion of procedural volume and timing recovery in Q2 2026
Watch Items
- FDA 510(k) Clearance for AI-assisted Reading FeatureTrigger: Anticipated clearance mid-2026Action: Initiate commercial launch in the U.S. shortly after clearance to drive workflow efficiency and revenue growth.
- Second-Generation CapsoCam Colon 510(k) SubmissionTrigger: Expected submission in Q3 2026Action: Complete the expanded pivotal study (targeting ~800 patients) and submit the Class II application to the FDA.
- U.S. Trade Policies and Tariff PressuresTrigger: Gross margin compression to 48% in Q1 2026Action: Monitor supply chain dependencies on Asia-based component suppliers and optimize manufacturing costs.
Research as of 19 Jun 2026